- ►usafp.org [PDF] T Rumbles, L Strikes, F Remains - Annals of Internal Medicine - Am Coll Physicians T he US Food and Drug Administration (FDA) has approved many pharmacotherapies for treating
diabe- tes on the basis of the drugs' ability to improve glycemic control. Although preventing adverse
macrovascular out- comes, such as myocardial infarction, is a desirable goal for treatment ... Related articles - All 2 versions
- ►annals.org GA Diamond, L Bax, S Kaul - Annals of Internal Medicine, 2007 - Am Coll Physicians A recent, widely publicized meta-analysis of 42 clinical trials concluded that rosiglitazone was
associated with an approximately 43% increased risk for myocardial infarction and an approximately
64% increased risk for cardiovascular death. The sensitivity of these conclusions to ... Cited by 124 - Related articles - BL Direct - All 5 versions
KM Richardson - mp.medscape.com The May 2007 online publication of the meta-analysis "Effect of Rosiglitazone on the Risk of
Myocardial Infarction and Death From Cardiovascular Causes," in The New England Journal
of Medicine (NEJM) launched a controversy that has been difficult to navigate. In an ... Related articles - All 3 versions
IJ Dahabreh - Clinical Trials, 2008 - ctj.sagepub.com Background A meta-analysis of randomized controlled trials suggested that rosiglitazone, a drug
used for the treatment of diabetes, may be associated with an increased risk of cardiovascular
adverse events. Three large randomized trials, designed specifically to address ... Cited by 22 - Related articles - BL Direct - All 2 versions
[CITATION] Rosiglitazone and Cardiovascular Disease—Recent Controversy
R PROHIBITED - secure.sherbornegibbs.com The recent publication by Nissen and Wolski in the New England Journal of Medicine1 on a
meta-analysis of selected trials carried out by GlaxoSmithKline using the thiazolidinedione rosiglitazone
represented a new low for this family of drugs. As everyone will by now be aware, this ... Related articles - View as HTML
ADO Progression - Diabetes & Vascular Disease Research - dvr.sagepub.com T he recent publication by Nissen and Wolski in the New England Journal of Medicine 1 on a
meta-analysis of selected trials carried out by GlaxoSmithKline using the thiazolidinedione rosiglitazone
represented a new low for this family of drugs. As everyone will by now be aware, this ... Related articles
[CITATION] Rosiglitazone and cardiovascular disease: a diabetologist's perspective
